Journal of Microbiology and Biotechnology
The Korean Society for Microbiology and Biotechnology publishes the Journal of Microbiology and Biotechnology.

2019 ; Vol.29-8: 1281~1287

AuthorYongmin Yan, Yanjing Wang, Jiali Qian, Sihui Wu, Yi Ji, Yanxiao Liu, Jian Zeng, Aihua Gong
Place of dutyKey Laboratory of Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, P.R. China
TitleNattokinase Crude Extract Inhibits Hepatocellular Carcinoma Growth in Mice
PublicationInfo J. Microbiol. Biotechnol.2019 ; Vol.29-8
AbstractNattokinase (NK, E.C. 3.4.21.62) is a serine protease produced by Bacillus subtilis natto that shows promise for the treatment of thrombotic disease. In this study, we assessed the effects of NK on the development of hepatocellular carcinoma (HCC), a principal malignancy of the liver that causes morbidity and mortality worldwide. Crude extracts of NK (NCE) were isolated from fermentation medium by centrifugation and separated into three fractions (<10 K, 100~30 K and >30K). Orthotopic HCC mouse models were established and NCE was administered by oral gavage. H&E staining was performed to examine the pathology of HCC livers. Immunohistochemistry and immunofluorescence were used to evaluate FOXM1, CD31, CD44 and vimentin expression in the liver. Compared to PBS groups, NCE increased the survival rates of HCC-bearing mice to 31% and decreased ascites. Low-intensity ultrasound imaging showed that the hypoechoic mass area was lower in NCE-treated mice and that tumor growth significantly decreased. IHC staining showed that the expression of FOXM1 was inhibited by NCE treatment. Immunofluorescence results revealed lower levels of CD31, CD44 and vimentin in the NCE groups. Taken together, these data demonstrate that NCE from Bacillus subtilis natto improves survival and inhibits tumor growth in HCC mice.
Full-Text
Key_wordHepatocellular carcinoma, nattokinase, tumor growth, cancer
References
  1. Nault JC, Galle PR, Marquardt JU. 2018. The role of molecular enrichment on future therapies in hepatocellular carcinoma. J. Hepatol. 69: 237-247.
    Pubmed CrossRef
  2. Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J, et al. 2017. Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). Hepatol. Commun. 1: 736-47.
    Pubmed CrossRef Pubmed Central
  3. Najjar M, Agrawal S, Emond JC, Halazun KJ. 2018. Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma. J. Hepatocell. Carcinoma 5: 17-28.
    Pubmed CrossRef Pubmed Central
  4. Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. 2018. Alpha-fetoprotein Slope >7.5 ng/ml/month predicts microvascular invasion and tumor recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 102: 816-822.
    Pubmed CrossRef Pubmed Central
  5. Weng Y, Yao J, Sparks S, Wang KY. 2017. Nattokinase: An oral antithrombotic agent for the prevention of cardiovascular disease. Int. J. Mol. Sci. 18.
    Pubmed CrossRef Pubmed Central
  6. Selvarajan E, Bhatnagar N. 2017. Nattokinase: an updated critical review on challenges and perspectives. Cardiovasc. Hematol. Agents Med. Chem. doi: 10.2174/1871525716666171207153332. [Epub ahead of print]
    Pubmed CrossRef
  7. Kotb E. 2014. The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi. Biotechnol. Prog. 30: 656-672.
    Pubmed CrossRef
  8. Fujita M, Ohnishi K, Takaoka S, Ogasawara K, Fukuyama R, Nakamuta H. 2011. Antihypertensive effects of continuous oral administration of nattokinase and its fragments in spontaneously hypertensive rats. Biol. Pharm. Bull. 34: 1696-1701.
    Pubmed CrossRef
  9. Kim JY, Gum SN, Paik JK, Lim HH, Kim KC, Ogasawara K, et al. 2008. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens. Res. 31: 1583-1588.
    Pubmed CrossRef
  10. Takano A, Hirata A, Ogasawara K, Sagara N, Inomata Y, Kawaji T, et al. 2006. Posterior vitreous detachment induced by nattokinase (subtilisin NAT): a novel enzyme for pharmacologic vitreolysis. Invest. Ophthalmol. Vis. Sci. 47: 2075-2079.
    Pubmed CrossRef
  11. Fadl NN, Ahmed HH, Booles HF, Sayed AH. 2013. Serrapeptase and nattokinase intervention for relieving Alzheimer’s disease pathophysiology in rat model. Hum. Exp. Toxicol. 32: 721-735.
    Pubmed CrossRef
  12. Chand V, Pandey A, Kopanja D, Guzman G, Raychaudhuri P. 2019. Opposing Roles of the Fork-head box genes FoxM1 and FoxA2 in Liver Cancer. Mol. Cancer Res. 17: 1063-1074.
    Pubmed CrossRef
  13. Guo D, Song X, Guo T, Gu S, Chang X, Su T, et al. 2018. Vimentin acetylation is involved in SIRT5-mediated hepatocellular carcinoma migration. Am. J. Cancer Res. 8: 2453-2466.
  14. Wada F, Koga H, Akiba J, Niizeki T, Iwamoto H, Ikezono Y, et al. 2018. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: potential targets by sulfasalazine. Cancer Sci. 109: 2801-2810.
    Pubmed CrossRef Pubmed Central
  15. Milewski D, Balli D, Ustiyan V, Le T, Dienemann H, Warth A, et al. 2017. FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas. PLoS Genet. 13: e1007097.
    Pubmed CrossRef Pubmed Central
  16. Zhang Bin, Liu Yuwan, Ji Qian, Zhao Mengmeng, Zeng Jian, Liu Lihua et al. 2017. Nattokinase Crude Extract Enhances Cutaneous Wound Healing. J. Biomater. Tissue Eng. 7: 1281-1286.
    CrossRef
  17. Man LL, Xiang DJ, Zhang CL. 2019. Strain screening from traditional fermented soybean foods and induction of Nattokinase production in Bacillus subtilis MX-6. Probiotics Antimicrob. Proteins 11: 283-294.
    Pubmed CrossRef
  18. Yin Y, L iu L , Zhao Z, Yin L , Bauer N, Nwaeburu CC, et al. 2018. Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer. Cancer Lett. 426: 14-24.
    Pubmed CrossRef
  19. Ma C, Wang F, Han B, Zhong X, Si F, Ye J, et al. 2018. SAL L 1 functions as a tumor suppressor in b reast cancer by regulating cancer cell senescence and metastasis through the NuRD complex. Mol. Cancer 17: 78.
    Pubmed CrossRef Pubmed Central
  20. Chatterji P, Rustgi AK. 2018. RNA Binding proteins in intestinal epithelial biology and colorectal cancer. Trends Mol. Med. 24: 490-506.
    Pubmed CrossRef Pubmed Central
  21. Incio J, L i gibel J A, M cManus D T, Suboj P , Jung K , Kawaguchi K, et al. 2018. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci. Transl. Med. 10(432).
    Pubmed CrossRef Pubmed Central
  22. Vaahtomeri K, Karaman S, Makinen T, Alitalo K. 2017. Lymphangiogenesis guidance by paracrine and pericellular factors. Genes Dev. 31: 1615-1634.
    Pubmed CrossRef Pubmed Central
  23. Murgai M, Ju W, Eason M, Kline J, Beury DW, Kaczanowska S, et al. 2017. KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat. Med. 23: 1176-90.
    Pubmed CrossRef Pubmed Central
  24. Suzuki Y, Kondo K, Matsumoto Y, Zhao BQ, Otsuguro K, Maeda T, et al. 2003. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sci. 73: 1289-1298.
    CrossRef
  25. Yao S , Fan LY, L am EW. 2 017. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance. Semin. Cancer Biol. 50: 77-89.
    Pubmed CrossRef Pubmed Central
  26. Yue M, L i S, Y an G , Li C, K ang Z. 2 018. P aeoniflorin inhibits cell growth and induces cell cycle arrest through inhibition of FoxM1 in colorectal cancer cells. Cell Cycle 17: 240-249.
    Pubmed CrossRef Pubmed Central
  27. Zaiden M, Feinshtein V, David A. 2017. Inhibition of CD44v3 and CD44v6 function blocks tumor invasion and metastatic colonization. J. Control. Release 257: 10-20.
    Pubmed CrossRef
  28. Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, et al. 2012. HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. Cancer Biol. Ther. 13: 198-205.
    Pubmed CrossRef
  29. Zhang X, Fournier MV, Ware JL, Bissell MJ, Yacoub A, Zehner ZE. 2009. Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol. Cancer Ther. 8: 499-508.
    Pubmed CrossRef Pubmed Central



Copyright © 2009 by the Korean Society for Microbiology and Biotechnology.
All right reserved. Mail to jmb@jmb.or.kr
Online ISSN: 1738-8872    Print ISSN: 1017-7825    Powered by INFOrang Co., Ltd